Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (NASDAQ: RXST) is an ophthalmic medical device company whose news flow centers on its Light Adjustable Lens system and corporate developments related to cataract surgery care. Company press releases describe RxSight as dedicated to providing high-quality customized vision to patients following cataract surgery through its Light Adjustable Lens (LAL/LAL+) and Light Delivery Device (LDD) platform.
News updates for RXST commonly include financial and operating results, such as quarterly revenue, procedure volumes for Light Adjustable Lenses, and the number of Light Delivery Devices sold and installed. These releases often discuss trends in LAL procedure volumes, changes in the installed base of LDDs, and guidance ranges for revenue and gross margin. Investors and observers can use these announcements to track how adoption of the Light Adjustable Lens system is progressing across cataract practices.
RxSight’s news also highlights corporate and leadership developments, including transitions in the Chief Financial Officer role and appointments to the Board of Directors and Board committees, as disclosed in press releases and related Form 8-K filings. In addition, the company regularly announces participation in major healthcare and ophthalmology conferences, where management presents to investors and engages with surgeons and other stakeholders.
Another recurring theme in RxSight’s news is commercial and clinical engagement activity. The company has reported initiatives such as practice development programs and Live Learning Sessions at ophthalmology meetings, where surgeons share real-world experience with the Light Adjustable Lens and discuss clinical and practice-level impacts.
This RXST news page aggregates these types of updates in one place, allowing readers to follow RxSight’s reported financial performance, leadership changes, conference participation, and initiatives related to its Light Adjustable Lens technology over time.
RxSight (RXST) reported strong Q4 and full-year 2024 financial results. Q4 revenue reached $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The LDD installed base expanded to 971 units.
Full-year 2024 revenue grew 57% to $139.9 million, with 98,055 LALs and 305 LDDs sold. Gross profit margin improved to 71.6% in Q4 2024, up from 61.8% in Q4 2023. The company reported a reduced Q4 net loss of $(5.9) million compared to $(9.2) million in Q4 2023.
For 2025, RxSight reaffirmed guidance projecting revenue of $185.0-197.0 million (32-41% growth), gross margin of 71-73%, and operating expenses of $165.0-170.0 million.
RxSight (RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has announced it will release its fourth quarter 2024 financial results on February 25, 2025, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone at (800) 715-9871 or (646) 307-1963 using conference code 7159871, or listen to the webcast through the company's investor relations website. A recording will be available after the call.
RxSight (NASDAQ: RXST) reported preliminary Q4 2024 revenue of $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The company's installed base reached 971 LDDs, a 46% increase from Q4 2023.
Full-year 2024 revenue is expected at $139.9 million, representing 57% growth, with 98,055 LALs sold and 305 LDDs installed. The company now serves approximately 15% of North American cataract surgeons, with LAL procedures representing over 10% of the region's premium IOL market.
For 2025, RxSight projects revenue between $185.0-197.0 million (32-41% growth), with gross profit margins of 71-73% and operating expenses of $165.0-170.0 million. Cash position as of December 31, 2024, was $237.2 million.
RxSight (NASDAQ: RXST), an ophthalmic medical device company focused on providing customized vision solutions for post-cataract surgery patients, has announced its participation in the upcoming J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.rxsight.com.
RxSight reported strong Q3 2024 financial results with revenue of $35.3 million, up 59% year-over-year. The company sold 24,554 Light Adjustable Lenses (LAL™/LAL+™), an 80% increase, and 78 Light Delivery Devices (LDD™s), an 18% increase from Q3 2023. The installed base grew to 888 LDDs, up 51% year-over-year. Gross profit reached $25.2 million with a 71.4% margin. Despite operating expenses of $34.4 million, net loss improved to $(6.3) million. The company raised its 2024 full-year revenue guidance to $140 million, with improved gross margin guidance of 70-71% and lower operating expenses.
RxSight announced it will release its Q3 2024 financial results on November 7, 2024, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Interested parties can join via phone at (888) 596-4144 or (646) 968-2525 using conference code 7406253. A live webcast will be available in listen-only mode through the investor relations website, with a recording accessible afterward.
RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, has announced its participation in two upcoming healthcare conferences in September 2024. The company will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 9:15 a.m. ET in New York City, and the Wells Fargo 2024 Healthcare Conference on September 5 at 3:45 p.m. ET in Boston.
RxSight specializes in providing high-quality customized vision to patients following cataract surgery. Both conference appearances will feature fireside chats with company representatives. Interested parties can access live and archived webcasts of these events through the company's investor relations website at https://investors.rxsight.com/.
RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q2 2024. Revenue increased 68% to $34.9 million, driven by a 92% increase in Light Adjustable Lens (LAL) sales and 32% growth in Light Delivery Device (LDD) revenue. The company sold 24,214 LALs and 78 LDDs, expanding its installed base to 810 LDDs. Gross profit rose 102% to $24.3 million, with a margin of 69.5%. Despite higher operating expenses, the net loss narrowed to $(6.1) million, or $(0.16) per share. RxSight raised its 2024 guidance, projecting revenue of $139-140 million and operating expenses of $135-136 million. The company's cash position strengthened to $233.3 million, bolstered by a recent public offering.
RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, has announced it will release its second quarter 2024 financial results on August 5, 2024, after market close. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results. Interested parties can register for the call, with a recommendation to join ten minutes early to ensure proper setup. A dial-in option will be available, and the call will be live-streamed and archived for one year on the company's investor relations website.
RxSight, a company specializing in ophthalmic medical devices, announced its participation in the Truist Securities Medtech Conference. The event will include a fireside chat with RxSight's management on June 18, 2024, at 12:05 p.m. Pacific Time / 3:05 p.m. Eastern Time. A live and archived webcast of the presentation will be available on their investor relations website.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
